Evolving Aspects of Colorectal Carcinoma
|
|
Purpose
|
|
This program will update gastroenterologists about the latest techniques for discovering adenomas in an effort to improve the overall prognosis of colorectal adenocarcinoma.
|
|
|
Program Overview
|
|
|
Colorectal cancer is one of the most frequently diagnosed carcinomas in the United States and the second leading cause of cancer death in the United States and North America. It is probably the most preventable form of cancer because it begins as premalignant adenoma. If these adenomas are detected early and removed many cases of colorectal cancer can be prevented.
|
|
|
Audience
|
|
|
This program has been specifically developed to update and educate gastroenterologists and primary care physicians who provide care for people with gastrointestinal disease.
|
|
|
Learning Objectives
|
Following completion of this CME activity, participants should be better able to:
- Identify the current screening recommendations and preventive strategies for colorectal cancer
- Understand the environmental and genetic factors that are linked to colorectal cancer
- Recognize the strengths and limitationsof various diagnostic procedures for colorectal cancer
- Explain the various strategies for treating colorectal cancer.
|
|
|
Disclaimer
|
|
The views expressed herein, while consistent with current medical literature, are solely those of the faculty.
|
|
|
Faculty
|
|
|
P. Jay Pasricha, MD (Program Director)
Professor of Anatomy and Neurosciences and Biomedical Engineering
University of Texas Medical Branch
>> Read Biography
Emmet B. Keeffe, MD (moderator)
Professor of Medicine
Stanford University School of Medicine
>> Read Biography
Steven H. Itzkowitz, MD
Professor of Medicine
Mount Sinai School of Medicine
>> Read Biography
David Lieberman, MD
Professor of Medicine
Oregon Health Sciences University
>> Read Biography
|
|
|
Faculty Disclosure Information
|
|
|
It is the policy of the AGA to assure balance, independence, objectivity and scientific rigor in all of its directly and jointly sponsored educational activities. All faculty including program committee chairs and planning members participating in any AGA sponsored or jointly-sponsored activity are expected to disclose to the participants any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias. In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support, faculty members for this activity were each asked to complete financial disclosure forms. Disclosures are provided below.
P. Jay Pasricha, MD
Grant/Research Support: Olympus
Consultant: USGI, GI Supply
Emmet B. Keeffe, MD
Nothing to Disclose
Steven H. Itzkowitz, MD
Scientific Advisory Board: EXACT Sciences Corporation
Speaker's Bureau: AstraZeneca, Myriad Genetics Laboratories
Research Support: EXACT Sciences Corporation
David Lieberman, MD
Scientific Advisory Board: EXACT Sciences Corporation
|
|
|
Suggested Minimum Software Requirements
|
|
|
Internet Explorer (4.0 or greater), Windows 98 and Windows Media Player (7.0 or greater), or Adobe Acrobat (5.0 or greater)
|
|
|
Release Date
|
|
|
May 14, 2005
|
|
|
Expiration Date
|
|
|
May 14, 2007
|
|
|
Fee
|
|
|
Free-of-charge
|
|
|
|
Sponsorship and Support
|
|
|
Sponsored by the AGA. Supported through an educational grant from TAP Pharmaceutical Products, Inc.
|
|
|
|
|
|
|
|
